Jemperli a Key Oncology Drug for GSK In the first nine months of 2024, Jemperli recorded sales worth £318 million. Sales of the drug are being driven by new patient starts in the United States.
European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...
The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or ...
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of adult patients with primary advanced or recurrent ...
GSK’s Jemperli (dostarlimab) has been granted expanded approval by the European Commission (EC) to treat a broader range of endometrial cancer patients. The PD-1-blocking antibody has been authorised ...
GSK plc announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary ...
GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...